Drug intelligence / Profile preview

NVS451

Development stage: Unknown
Lead developer: Sinopharm Zhongsheng Biotechnology Research Institute
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

NVS451 is a recombinant fusion protein under development as an injectable therapy for moderate to severe plaque psoriasis. It is being evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy in both healthy volunteers and patients with moderate to severe plaque psoriasis. The precise mechanism of action has not been disclosed publicly as of June 2025. The drug is administered subcutaneously and was initially developed by Sinopharm Zhongsheng Biotechnology Research Institute.

Other names: NVS451 fusion proteinNVS-451 fusion proteinNVS 451 fusion protein

Beyond the preview

Go deeper on NVS451.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVS451.

Explore the full profile